Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of intravenous vedolizumab in pediatric chronic active pouchitis
MOH_2024-02-22_013274Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vedolizumab in pouchitis, sponsored by Takeda. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
vedolizumab
03
Conditions
pouchitis
Beyond the preview
Go deeper on MOH_2024-02-22_013274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-22_013274.